Objective: To discuss the association between FGFR4 gene polymorphism rs351855 (Glu388Aly) and the susceptibility and chemotherapeutic effect of cervical cancer infected by high-risk type HPV. Methods:A total of 162 patients with high-risk HPV cervical cancer and 162 healthy women were collected and the genotypes of the FGFR4 rs351855 locus were detected. The genotype distributions in the two groups were compared. The cervical cancer patients were divided into four groups which namely good therapeutic effect group and bad therapeutic effect, recurrence or metastasis and no recurrence or metastasis group respectively, and the risks of different genotype on the curative effect and prognosis were analyzed by Logistic regression. The survival time of patients with different genotypes was compared. Results:There was no statistic difference in FGFR4 rs351855 genotype distribution between the patients group and control group (P>0.05), among which the risk of chemotherapy failure on GA+AA patients was 3.257 times as much as that of the GG patients, and the risk of recurrence or metastasis of GA+AA patients was 2.783 times as much as that of the GG patients. For AA patients, the risk of chemotherapy failure and the risk of relapse and metastasis are 3.833 and 3.406 times, respectively, as much as that that of the GG patients. The overall survival of GA and AA patients was shorter than that of the GG patients, and significant difference was found (χ2=7.098, P=0.029). The difference in overall survival between CGA+AA patients and GG patients was almost statistically significant (χ2=3.634, P=0.057).onclusions:The FGFR4 rs351855 polymorphism is not associated with the susceptibility of high-risk HPV cervical cancer, but patients with gene A was at higher risk of unfavourable chemotherapy prognosis compared with patients with GG.